FPS

CompletedResults posted

Effects of Obesity Treatments on Food Preferences and Metabolism

The Effects of Current Treatments of Obesity on Food Preferences, Gut Hormones, Bile Acids and Hepatic Glucose Output in Humans.

Lead sponsor

Imperial College London

Assets

Exenatide / Liraglutide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Bariatric Surgery Candidate, Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoints

•Energy intake kcal change•Energy Intake

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01724060

Org study IDFPS

Timeline

Milestones

Study first posted2012-11-09estimated

Last update posted2020-03-31actual

Results first posted2020-03-31actual

Study start2012-09 (month precision)

Primary completion2017-10actual (month precision)

Study completion2017-10actual (month precision)

Assets

Investigational agents

Exenatide Liraglutide

Study populations

Who this study enrolls

Bariatric Surgery CandidateObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Sampling methodNon probability sample

Study population text

Patients from the community or hospital care

Inclusion criteria

•Adult patients with overweight and/or obesity (BMI ≥30 Kg/m2) who are eligible for obesity treatment based on NICE guidance or that are having non bariatric surgery or endoscopy.

Exclusion criteria

•None

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

Patient-reported / QoL

Other clinical outcomes

Glycemic / diabetes

2 endpoints

Secondary/registry result

Change in Hepatic Insulin Resistance From Baseline

Time frame:Change at 1 week after intervention

change from baseline, improvement

Secondary/protocol endpoint

Change in Hepatic Insulin Resistance From Baseline

Time frame:Change at 1 week after intervention

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Patient-reported / QoL

2 endpoints

Secondary/registry result

Change in Appetite Ratings From Baseline

Time frame:Change 12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Appetite Ratings From Baseline

Time frame:Change 12 months

change from baseline, improvement

Other clinical outcomes

1 endpoint

Primary/registry result

Change in Energy Intake From Baseline

Time frame:Change at 12 months

energy intake kcal change

change from baseline, improvement

Posted result

Group	Value (mean), kcal	95% CI
Gastric Bypass	500	—
Gastric Banding	310	—
Sleeve Gastrectomy	482	—
Endobarrier	5	—
Exenatide	27	—
Liraglutide	103	—
Lifestyle	11	—
Elective Surgery or Endoscopy	15	—

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

Change in Energy Intake From Baseline

Time frame:Change at 12 months

change from baseline, improvement

Secondary/registry result/low confidence

Change in Metabolites From Baseline

Time frame:Change at 12 months

change from baseline, descriptive

Secondary/registry result/low confidence

Change in Macronutrient Composition From Baseline

Time frame:Change at 12 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in Metabolites From Baseline

Time frame:Change at 12 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in Macronutrient Composition From Baseline

Time frame:Change at 12 months

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.